Share buyback sets the stage for renewed focus on Novo Nordisk Novo Nordisk (NVO) triggered fresh attention after launching a DKK 15b share repurchase programme, committing up to DKK 11.2b to B shares through early 2027 and already retiring tens of millions of shares. For investors watching Novo Nordisk, the backdrop to this buyback is a share price that has slipped to US$38.06, with the 30-day share price return down 11.63% and the year-to-date share price return down 27.35%. The 1-year total shareholder return has declined 30.54%, pointing to fading momentum even as Wegovy pill approval, higher 2026 guidance, and intensifying GLP-1 competition all reshape how the market prices both its growth potential and risk profile.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.